Accueil › Cancer métastatique › Nouveau-Mexique › Albuquerque
Essais cliniques pour Cancer métastatique à Albuquerque, NM
12 études pour Cancer métastatique recherchent des participants dans et autour de Albuquerque (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Recrutement en coursPhase 2
- University of New Mexico Cancer Center, Albuquerque
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Recrutement en coursPhase 2/3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Recrutement en coursPhase 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Recrutement en coursPhase 3
- Research Site, Albuquerque
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Recrutement en coursÉtude observationnelle
- New Mexico Oncology Hematology Consultants, Albuquerque
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Recrutement en coursPhase 3
- Optimum Clinical Research Group, Albuquerque
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- University of New Mexico Comprehensive Cancer Center, Albuquerque
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Recrutement en coursPhase 3
- Research Site, Albuquerque
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Recrutement en coursPhase 1
- New Mexico Oncology Hematology Consultants Ltd, Albuquerque
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Recrutement en coursPhase 1/2
- Presbyterian Kaseman Hospital (site 208), Albuquerque
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Albuquerque
Essais pour Cancer métastatique dans d'autres villes
- Houston, TX104 études
- New York City, NY93 études
- Nashville, TN70 études
- Boston, MA63 études
- Los Angeles, CA57 études
- St. Louis, MO54 études
- Arlington, VA53 études
- Philadelphia, PA46 études
- Chicago, IL45 études
- San Antonio, TX44 études
- Washington, DC43 études
- Dallas, TX42 études
Autres études à Albuquerque
- Cancer du poumon non à petites cellules18 études
- Cancer du sein17 études
- Cancer de l'ovaire15 études
- Cancer (tous types)14 études
- Cancer du poumon14 études
- Cancer de l'endomètre12 études
- Diabète de type 211 études
- Maladie cardiovasculaire10 études
- Mélanome9 études
- Leucémie aiguë myéloïde9 études
- Cancer de la prostate9 études
- Maladie rénale chronique8 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.